Dr. Jamie Dwyer, Professor of Medicine at Vanderbilt University Joins Draganfly Board of Advisors

Rhea-AI Summary

Draganfly Inc. (OTCQB: DFLYF) has appointed Dr. Jamie P. Dwyer to its Board of Advisors, enhancing its expertise in FDA processes relevant to its Vital Intelligence technology. Dr. Dwyer, a professor at Vanderbilt University and co-founder of Innovative Renal Care, brings significant medical and regulatory experience to Draganfly. CEO Cameron Chell expressed excitement over Dr. Dwyer’s role in advancing the company's telehealth initiatives. Draganfly has previously strengthened its advisory team with notable figures from various sectors.

Positive

• Appointment of Dr. Jamie Dwyer adds expertise in FDA processes.
• Strengthened advisory board could enhance strategic initiatives.

Negative

• None.

Los Angeles, CA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, today announced, subject to customary governance approvals, Jamie P. Dwyer M.D. has joined as a member of the Board of Advisors of Draganfly.

Dr. Dwyer is a professor of medicine at Vanderbilt University, President of the Collaborative Study Group, and Co-Founder of Innovative Renal Care. Previously he served on the faculty of Mayo Clinic.

Dr. Dwyer has extensive experience working with FDA processes in particular devices and software.

Cameron Chell, CEO of Draganfly, said: “We are excited and truly honored to have Dr. Jamie Dwyer join Draganfly’s outstanding Board of Advisors. Dr. Dwyer brings an incredible understanding and experience with FDA processes and will be key in evolving our Vital Intelligence technology.”

“Draganfly has impressed me with the work they have done with their Smart Vital assessment platform and telehealth app. I am honored to assist a company that has built a solid foundation for innovation within the telehealth sector,” said Dr. Jamie Dwyer.

Dr. Dwyer holds an Sc.B degree in mathematics and Latin from Brown University, and an M.D. with Distinction from Brown University Medical School. He trained in Internal Medicine at Mayo Clinic Florida, where he served as Chief Medical Resident. He trained in Nephrology and Clinical Research at VUMC. After a faculty appointment at Mayo Clinic, he joined the Nephrology Division of VUMC in 2008.

Draganfly has recently augmented its team with other key leaders, including the following:

• Andrew H. Card, former White House Chief of Staff and U.S. Secretary of Transportation, joined the Company’s Board of Directors on November 7, 2019.
• Julie Myers Wood, CEO of Guidepost Solutions and former Assistant Secretary of Homeland Security, joined the Company’s Board of Advisors on March 3, 2020.
• Molly Wilkinson, Vice President of Regulatory Affairs at American Airlines and former Republican General Counsel for the U.S. Senate Committee on Homeland Security and Governmental Affairs, joined the Company’s Board of Advisors on March 12, 2020.
• Dr. Jack Chow, former U.S. Ambassador and Assistant Director-General of the World Health Organization on HIV/AIDS, Tuberculosis and Malaria, joined the Company’s Board of Advisors on April 8, 2020.
• Captain Lawrence Vincent (USN, Ret.), current Executive Officer, Defense Counter- Intelligence Agency, and former Operations Center Director for Naval and Marine Corps Forces in Europe and Africa, joined the Company’s Board of Advisors on April 16, 2020.
• John Mitnick, former General Counsel of the US Department of Homeland Security and Raytheon Senior Executive, the Company’s Board of Directors on June 18, 2020.
• Derek Anderson, Hall of Famer and Former NBA and NCAA Champion, joined the Company’s Board of Advisors on November 12, 2020.
• Rob Anson founded Loop Insights, Inc. (MTRX:TSXV) (RACMF:OTCQB) and Fobisuite Technologies, Inc., joined the Company’s Board of Advisors on December 17, 2020.

The Company also announces that it had entered into a marketing services agreement with AGORACOM effective December 30, 2020 pursuant to which the Company will pay AGORACOM fees in the aggregate amount of $75,000 plus applicable taxes for a one-year term. The fees will be paid by the issuance of common shares of the Company (“Common Shares”), subject to board approval. $15,000 of the Common Shares being payable upon the setup and creation of tools to be used in connection with the services, and an additional $15,000 of Common Shares being payable every three months thereafter for the remainder of the one-year term. The number and deemed price of the Common Shares to be issued will be determined after the date the services are provided in each period and are to be calculated using the closing price of the Common Shares on the Canadian Securities Exchange on each date on which Common Shares are to be issued.

About Draganfly

Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge drone solutions, software and AI systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leader serving the public safety, agriculture, industrial inspections, security, mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives.

For more information on Draganfly, please visit us at www.draganfly.com.

For additional investor information, visit https://www.thecse.com/en/listings/technology/draganfly- inc, https://www.otcmarkets.com/stock/DFLYF/overview or https://www.boerse-frankfurt.de/aktie/ draganfly-inc

Media Contact

Arian Hopkins
email: media@draganfly.com

Company Contact
email: info@draganfly.com

Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking ‎‎‎‎‎‎‎information” as ‎defined under applicable Canadian securities laws. Forward-looking statements ‎‎‎‎‎‎‎and information can ‎generally be identified by the use of forward-looking terminology such as ‎‎‎‎‎‎‎‎“may”, “will”, “expect”, “intend”, ‎‎“estimate”, “anticipate”, “believe”, “continue”, “plans” or similar ‎‎‎‎‎‎‎terminology. Forward-looking statements ‎and information are based on forecasts of future ‎‎‎‎‎‎‎results, estimates of amounts not yet determinable and ‎assumptions that, while believed by ‎‎‎‎‎‎‎management to be reasonable, are inherently subject to significant ‎business, economic and ‎‎‎‎‎‎‎competitive uncertainties and contingencies. ‎Forward-‎‎‎‎looking ‎statements and ‎information are subject to various ‎known and unknown risks and ‎‎‎‎‎uncertainties, ‎many of which are ‎beyond the ability of the ‎Company to control or predict, that ‎‎‎‎may cause ‎the ‎Company’s actual ‎results, performance or ‎achievements to be materially different ‎‎‎‎from those ‎‎expressed or implied ‎thereby, and are ‎developed based on assumptions about such ‎‎‎‎risks, ‎uncertainties ‎and other ‎factors set out here ‎in, including but not limited to: the potential ‎‎‎‎impact of ‎epidemics, ‎pandemics ‎or other public ‎health crises, including the current outbreak of ‎‎‎‎the novel ‎coronavirus known as ‎‎COVID-19 on the ‎Company’s business, operations and financial ‎‎‎‎condition, ‎the successful ‎integration of ‎‎technology, the inherent risks involved in the general ‎‎‎‎securities ‎markets; ‎uncertainties relating to ‎the ‎availability and costs of financing needed in the ‎‎‎‎future; the ‎inherent ‎uncertainty of cost ‎estimates and the ‎potential for unexpected costs and ‎‎‎‎expenses, ‎currency ‎fluctuations; regulatory ‎restrictions, liability, ‎competition, loss of key ‎‎‎‎employees and ‎other ‎related risks and uncertainties ‎disclosed under the ‎heading “Risk Factors“ ‎‎‎‎in the Company’s ‎most ‎recent filings filed with ‎securities regulators in Canada on ‎the SEDAR ‎‎‎‎website at ‎www.sedar.com. ‎The Company ‎undertakes no obligation to update forward-‎looking ‎‎‎‎information ‎except as required ‎by applicable ‎law. Such forward-looking information represents ‎‎‎‎‎‎managements’ best judgment ‎based on ‎information currently available. No forward-looking ‎‎‎‎‎statement ‎can be guaranteed and ‎actual ‎future results may vary materially. Accordingly, readers ‎‎‎‎‎are advised not to ‎place undue ‎reliance ‎on forward-looking statements or information.‎

FAQ

What is the significance of Dr. Jamie Dwyer's appointment to Draganfly's Board of Advisors on February 9, 2021?

Dr. Jamie Dwyer's appointment is significant as he brings extensive experience with FDA processes, crucial for advancing Draganfly's Vital Intelligence technology.

How does Draganfly plan to utilize Dr. Dwyer's expertise in telehealth?

Draganfly aims to leverage Dr. Dwyer's expertise to evolve its Smart Vital assessment platform and enhance its telehealth applications.

What is the stock symbol for Draganfly?

The stock symbol for Draganfly is DFLYF, listed on OTCQB.

Who else has joined Draganfly's advisory team recently?

Recently, notable additions include Andrew H. Card and Julie Myers Wood, enhancing the board's strategic capabilities.

What is the focus area of Draganfly's business?

Draganfly specializes in drone solutions, software, and AI systems for various sectors, including public safety and telehealth.